In the latest trading session, 1.42 million Sage Therapeutics Inc (NASDAQ:SAGE) shares changed hands as the company’s beta touched 0.86. With the company’s most recent per share price at $7.46 changed hands at -$0.04 or -0.52% at last look, the market valuation stands at $456.43M. SAGE’s current price is a discount, trading about -270.91% off its 52-week high of $27.67. The share price had its 52-week low at $4.62, which suggests the last value was 38.07% up since then. When we look at Sage Therapeutics Inc’s average trading volume, we note the 10-day average is 2.3 million shares, with the 3-month average coming to 1.25 million.
Analysts gave the Sage Therapeutics Inc (SAGE) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.78. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended SAGE as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Sage Therapeutics Inc’s EPS for the current quarter is expected to be -1.38.
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
Instantly SAGE was in red as seen in intraday trades today. With action 19.95%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 37.41%, with the 5-day performance at 19.95% in the green. However, in the 30-day time frame, Sage Therapeutics Inc (NASDAQ:SAGE) is 26.68% up. Looking at the short shares, we see there were 4.83 million shares sold at short interest cover period of 3.46 days.
The consensus price target for the stock as assigned by Wall Street analysts is 13, meaning bulls need an upside of 42.62% from its recent market value. According to analyst projections, SAGE’s forecast low is 5 with 26 as the target high. To hit the forecast high, the stock’s price needs a -248.53% plunge from its current level, while the stock would need to tank 32.98% for it to hit the projected low.
Sage Therapeutics Inc (SAGE) estimates and forecasts
Data shows that the Sage Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -36.77% over the past 6 months, a 28.73% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach -51.16% down from the last financial year.
Consensus estimates given by 16 financial analysts project the company’s revenue in the current quarter to hit an average of 14.11M. 7 analysts are of the opinion that Sage Therapeutics Inc’s revenue for the current quarter will be 15.83M. The company’s revenue for the corresponding quarters a year ago was 77.97M and 7.9M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -81.90%. The estimates for the next quarter sales put growth at 100.33%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.28%. The 2025 estimates are for Sage Therapeutics Inc earnings to increase by 28.60%.
SAGE Dividends
Sage Therapeutics Inc is expected to release its next quarterly earnings report in February.
Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.92% of Sage Therapeutics Inc shares while 86.39% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.08%. There are 86.39% institutions holding the Sage Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 10.6696% of the shares, roughly 6.42 million SAGE shares worth $69.68 million.
FMR LLC holds the second largest percentage of outstanding shares, with 9.6836% or 5.82 million shares worth $63.24 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 1.71 shares estimated at $12.76 million under it, the former controlled 2.80% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 2.62% of the shares, roughly 1.6 shares worth around $11.95 million.
